1. Home
  2. JELD vs MXCT Comparison

JELD vs MXCT Comparison

Compare JELD & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JELD-WEN Holding Inc.

JELD

JELD-WEN Holding Inc.

HOLD

Current Price

$1.80

Market Cap

152.5M

ML Signal

HOLD

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$1.19

Market Cap

129.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JELD
MXCT
Founded
1960
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.5M
129.6M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
JELD
MXCT
Price
$1.80
$1.19
Analyst Decision
Hold
Buy
Analyst Count
6
4
Target Price
$3.43
$5.50
AVG Volume (30 Days)
1.4M
902.6K
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,211,181,000.00
$33,026,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.06
$18.50
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.93
$0.64
52 Week High
$6.98
$2.37

Technical Indicators

Market Signals
Indicator
JELD
MXCT
Relative Strength Index (RSI) 51.38 61.43
Support Level $1.64 $1.08
Resistance Level $2.15 $1.30
Average True Range (ATR) 0.19 0.07
MACD -0.03 -0.01
Stochastic Oscillator 36.36 60.47

Price Performance

Historical Comparison
JELD
MXCT

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: